Page 2 - Cingulate News Today

Cingulate Inc. (NASDAQ:CING – Get Free Report) was the target of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 33,500 shares, a drop of 68.0% from the June 15th total of 104,800 shares. Based on an average daily trading volume, of 337,700 shares, […]

Cingulate Inc. (NASDAQ:CING – Get Free Report) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 33,500 shares, a decrease of 68.0% from the June 15th total of 104,800 shares. Approximately 0.4% of the shares of the company are sold short. Based on […]

08.06.2023 - Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June 08, 2023 (GLOBE NEWSWIRE) - Cingulate Inc. ... Seite 1

Cingulate Inc. (NASDAQ:CING – Get Rating) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 156,700 shares, a decrease of 45.5% from the April 30th total of 287,700 shares. Based on an average trading volume of 838,400 shares, the short-interest […]

KANSAS CITY, Kan., May 25, 2023 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a... | May 25, 2023

Cingulate (NASDAQ:CING – Get Rating) posted its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.08), reports. Cingulate Price Performance Shares of NASDAQ:CING opened at $1.02 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.12 […]

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for...

Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial ProgramKANSAS CITY, Kan., May 03, 2023 -- Cingulate Inc. ,... | May 3, 2023

Cingulate Announces Successful Transfer of CTx-1301 Proprietary PTR™ Manufacturing Processes to Societal CDMO Scalable Supply of CTx-1301 Ready to be... | May 3, 2023

KANSAS CITY, Kan., April 14, 2023 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a... | April 14, 2023